avacopan CAS: 1346623-17-3

CAS NO: 1346623-17-3
avacopan
Chemical Name: Budiodarone tartrate
Molecular Formula: C33H35F4N3O2
Formula Weight: 581.64
CAS No.: 1346623-17-3
Description Review
Description

Avacopan CAS: 1346623-17-3 is a new medication that is being researched for its therapeutic effects. This medication is a type of drug known as a C5a receptor inhibitor. It is currently in development for the treatment of various medical conditions such as vasculitis and other inflammatory disorders. This article will provide you with more information about avacopan.

Chemical name:

The chemical name of avacopan is N-((S)-1-(4-(6-ethoxy-5-oxo-4,5-dihydropyrimidin-2-yl)phenyl)ethyl)-4-(naphthalene-1-ylmethyl)piperazine-1-carboxamide.

Molecular formula:

The molecular formula of avacopan is C33H37N5O3.

Formula weight:

The formula weight of avacopan is 551.69 g/mol.

CAS No:

The CAS number for avacopan is 1346623-17-3.

Top ten keywords from Google and synonyms:

  1. Avacopan for vasculitis
  2. C5a receptor inhibitor
  3. Anti-inflammatory drug
  4. N-((S)-1-(4-(6-ethoxy-5-oxo-4,5-dihydropyrimidin-2-yl)phenyl)ethyl)-4-(naphthalene-1-ylmethyl)piperazine-1-carboxamide
  5. Complement system inhibitor
  6. Clinical trials for avacopan
  7. Potential benefits of avacopan
  8. Immune system disorders
  9. Neutrophil recruitment inhibition
  10. Treatment for rare diseases

Health benefits of this product:

Avacopan is a selective C5a receptor inhibitor that has been shown to have potential therapeutic benefits for several immune system disorders, including vasculitis, a rare condition that leads to inflammation of blood vessels. It is also being evaluated for its anti-inflammatory and anti-fibrotic effects in other conditions such as lupus nephritis, focal segmental glomerulosclerosis (FSGS), and certain dermatologic diseases.

Potential effects:

Avacopan has shown promising results in early clinical trials for the treatment of vasculitis. It has the potential to selectively block the C5a receptor, which plays a role in the neutrophil recruitment and activation, and ultimately inflammation. By blocking this receptor, avacopan could reduce inflammation in patients with vasculitis and other inflammatory conditions.

Product mechanism:

The complement system is a part of the immune system that plays a role in inflammation and the control of infectious agents. One of the important components of the complement system is C5a, which binds to its receptor and promotes the recruitment and activation of neutrophils at sites of inflammation. Avacopan works by specifically inhibiting the interaction between C5a and its receptor, thus reducing the recruitment and activation of neutrophils, and reducing inflammation in tissues.

Safety:

Avacopan has been shown to be well tolerated in clinical trials. However, as with any medication, some side effects may occur. Some of the known potential side effects of avacopan include diarrhea, nausea, and headaches. Patients should always consult their healthcare provider before starting any new medication.

Side effects:

The side effects of avacopan are generally mild and include diarrhea, nausea, and headaches, which are common with many medications. However, severe side effects may occur in some cases. Patients should always inform their healthcare provider if they experience any unusual symptoms while taking avacopan

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code